Serious adverse events · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).
1 finding from 1 review
Serious adverse events (6 months · children with stable wrist fracture, predominantly buckle (torus) fracturesa
1 finding from 1 review
Serious adverse events ( · children with either displaced distal radius fracture with intact or displaced ulna fracture (both‐bone fracture), or minimally displaced…
1 finding from 1 review
Total serious adverse events · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).
1 finding from 1 review
Serious adverse events · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
1 finding from 1 review
Serious adverse events · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (3 to 4 weeks · children with stable wrist fracture, predominantly buckle (torus) fracturesa
1 finding from 1 review
Non‐serious adverse events · farmworkers
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with other antibiotics (very low certainty).
1 finding from 1 review
Non‐serious adverse events · farmworkers, soldiers, and people in endemic areas
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
1 finding from 1 review
Serious adverse events/death · rehabilitation vs less time spent
Summary of findings table ‐ More time showed no clear difference in serious adverse events/death compared with less time (low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin detemir (low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
1 finding from 1 review
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Serious adverse events · children with respiratory syncytial virus infection
Summary of findings table ‐ Immunoglobulins showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review